Recent Advances in Cancer Immunotherapy with a Focus on FDA-Approved Vaccines and Neoantigen-Based Vaccines

Overview

Journal Vaccines (Basel)

Date 2023 Nov 25

PMID 38005965

Authors

Anna Hargrave

Abu Salim Mustafa

Asma Hanif

Javed H Tunio

Shumaila Nida M Hanif

Affiliations

Soon will be listed here.

Abstract

Cancer immunotherapies refer to the concept of retraining the immune system to target malignant cells. Multiple immunotherapeutic options exist including immune modulating antibodies, immune stimulating cytokines, chimeric antigen receptor T cell therapy, and vaccines. Overall, this field has advanced rapidly as knowledge of the tumor microenvironment, immunological pathways, and biotechnology expands. Specifically, advancements in neoantigen identification, characterization, and formulation into a vaccine show promise. This review is focused on previously United States Food and Drug Administration-approved cancer therapeutic vaccines and neoantigen-based vaccine developments along with the associated relevant clinical trials.

Citing Articles

Vaccine-Based Immunotherapy for Oropharyngeal and Nasopharyngeal Cancers.

Filippini D, Broseghini E, Liberale C, Gallerani G, Siepe G, Nobili E J Clin Med. 2025; 14(4).

PMID: 40004705 PMC: 11856027. DOI: 10.3390/jcm14041170.

Humanized Mouse Models for Immuno-Oncology Research: A Review and Implications in Lung Cancer Research.

Park C, Khalil M, Pham N, Wong S, Ly D, Sacher A JTO Clin Res Rep. 2025; 6(3):100781.

PMID: 39990135 PMC: 11847118. DOI: 10.1016/j.jtocrr.2024.100781.

Immunotherapy in Recurrent Ovarian Cancer.

Chen K, Wang J, Yang M, Deng S, Sun L Biomedicines. 2025; 13(1).

PMID: 39857752 PMC: 11762523. DOI: 10.3390/biomedicines13010168.

Fabrication and functional validation of a hybrid biomimetic nanovaccine (HBNV) against -mutant melanoma.

Poudel K, Ji Z, Njauw C, Rajadurai A, Bhayana B, Sullivan R Bioact Mater. 2025; 46():347-364.

PMID: 39834347 PMC: 11742834. DOI: 10.1016/j.bioactmat.2024.12.023.

Cancer vaccines: an update on recent achievements and prospects for cancer therapy.

Chekaoui A, Garofalo M, Gad B, Staniszewska M, Chiaro J, Pancer K Clin Exp Med. 2024; 25(1):24.

PMID: 39720956 PMC: 11669620. DOI: 10.1007/s10238-024-01541-7.

References

Xie N, Shen G, Gao W, Huang Z, Huang C, Fu L . Neoantigens: promising targets for cancer therapy. Signal Transduct Target Ther. 2023; 8(1):9. PMC: 9816309. DOI: 10.1038/s41392-022-01270-x. View

Bidram M, Zhao Y, Shebardina N, Baldin A, Bazhin A, Ganjalikhany M . mRNA-Based Cancer Vaccines: A Therapeutic Strategy for the Treatment of Melanoma Patients. Vaccines (Basel). 2021; 9(10). PMC: 8540049. DOI: 10.3390/vaccines9101060. View

Zhang Y, Lin S, Wang X, Zhu G . Nanovaccines for cancer immunotherapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2019; 11(5):e1559. PMC: 7040494. DOI: 10.1002/wnan.1559. View

Bulik-Sullivan B, Busby J, Palmer C, Davis M, Murphy T, Clark A . Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification. Nat Biotechnol. 2018; . DOI: 10.1038/nbt.4313. View

Nordin M, Azemi A, Nordin A, Nabgan W, Ng P, Yusoff K . Peptide-Based Vaccine against Breast Cancer: Recent Advances and Prospects. Pharmaceuticals (Basel). 2023; 16(7). PMC: 10386531. DOI: 10.3390/ph16070923. View

Waldman A, Fritz J, Lenardo M . A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020; 20(11):651-668. PMC: 7238960. DOI: 10.1038/s41577-020-0306-5. View

DeMaria P, Bilusic M . Cancer Vaccines. Hematol Oncol Clin North Am. 2019; 33(2):199-214. DOI: 10.1016/j.hoc.2018.12.001. View

Buonaguro L, Tagliamonte M . Peptide-based vaccine for cancer therapies. Front Immunol. 2023; 14:1210044. PMC: 10467431. DOI: 10.3389/fimmu.2023.1210044. View

Klepsch V, Siegmund K, Baier G . Emerging Next-Generation Target for Cancer Immunotherapy Research: The Orphan Nuclear Receptor NR2F6. Cancers (Basel). 2021; 13(11). PMC: 8197903. DOI: 10.3390/cancers13112600. View

10.

Sydow E, Mustafa A, Hanif A, Tunio J, Hanif S . Recent Updates on mRNA Vaccines. Vaccines (Basel). 2022; 10(8). PMC: 9416164. DOI: 10.3390/vaccines10081209. View

11.

Zhang Z, Lu M, Qin Y, Gao W, Tao L, Su W . Neoantigen: A New Breakthrough in Tumor Immunotherapy. Front Immunol. 2021; 12:672356. PMC: 8085349. DOI: 10.3389/fimmu.2021.672356. View

12.

Ott P, Hu-Lieskovan S, Chmielowski B, Govindan R, Naing A, Bhardwaj N . A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer. Cell. 2020; 183(2):347-362.e24. DOI: 10.1016/j.cell.2020.08.053. View

13.

Gide T, Pires da Silva I, Quek C, Ferguson P, Batten M, Shang P . Clinical and Molecular Heterogeneity in Patients with Innate Resistance to Anti-PD-1 +/- Anti-CTLA-4 Immunotherapy in Metastatic Melanoma Reveals Distinct Therapeutic Targets. Cancers (Basel). 2021; 13(13). PMC: 8267740. DOI: 10.3390/cancers13133186. View

14.

Redelman-Sidi G, Glickman M, Bochner B . The mechanism of action of BCG therapy for bladder cancer--a current perspective. Nat Rev Urol. 2014; 11(3):153-62. DOI: 10.1038/nrurol.2014.15. View

15.

Blass E, Ott P . Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat Rev Clin Oncol. 2021; 18(4):215-229. PMC: 7816749. DOI: 10.1038/s41571-020-00460-2. View

16.

Burugu S, Dancsok A, Nielsen T . Emerging targets in cancer immunotherapy. Semin Cancer Biol. 2017; 52(Pt 2):39-52. DOI: 10.1016/j.semcancer.2017.10.001. View

17.

Zhang R, Yuan F, Shu Y, Tian Y, Zhou B, Yi L . Personalized neoantigen-pulsed dendritic cell vaccines show superior immunogenicity to neoantigen-adjuvant vaccines in mouse tumor models. Cancer Immunol Immunother. 2019; 69(1):135-145. PMC: 6949210. DOI: 10.1007/s00262-019-02448-z. View

18.

Boldicke T . Therapeutic Potential of Intrabodies for Cancer Immunotherapy: Current Status and Future Directions. Antibodies (Basel). 2022; 11(3). PMC: 9326752. DOI: 10.3390/antib11030049. View

19.

Schiller J, Lowy D . Vaccines to prevent infections by oncoviruses. Annu Rev Microbiol. 2010; 64:23-41. PMC: 6264788. DOI: 10.1146/annurev.micro.112408.134019. View

20.

Biswas N, Chakrabarti S, Padul V, Jones L, Ashili S . Designing neoantigen cancer vaccines, trials, and outcomes. Front Immunol. 2023; 14:1105420. PMC: 9947792. DOI: 10.3389/fimmu.2023.1105420. View